NanoViricides' NV-387 Advances to Phase II Trials, Showcases Anti-Inflammatory Effects in Viral Infections and Metastatic Cancer Resurgence.

NanoViricides' drug candidate NV-387 is advancing to Phase II clinical trials for treating viral infections, including COVID-19, RSV, and Influenza. NV-387 has shown effectiveness in reducing inflammation linked to viral infections and metastatic cancer resurgence. It has outperformed existing treatments in animal models, demonstrating broad-spectrum applicability and potential to mitigate the resurgence of metastatic cancer.

NanoViricides, Inc. has announced that its lead drug candidate, NV-387, is advancing to Phase II clinical trials for the treatment of various viral infections, including COVID-19, RSV, and Influenza. This advancement follows the successful completion of Phase I clinical trials, showcasing NV-387's potential to reduce inflammation and prevent the resurgence of metastatic cancer caused by viral infections [1].

NV-387, a broad-spectrum antiviral drug, has demonstrated effectiveness in reducing inflammation, particularly the cytokine IL-6, which is linked to increased cancer risk. Animal model studies have shown that NV-387 outperforms existing treatments, such as ribavirin and oseltamivir, in protecting against lethal viral infections [2]. The drug's ability to calm the human immune system and reduce inflammation markers makes it a promising candidate for mitigating cancer resurgence.

The company's President and Chairman, Anil R. Diwan, Ph.D., noted that NV-387's unique properties could significantly impact cancer patients in remission who suffer from viral infections that could lead to cancer recurrence. This is particularly relevant given the ongoing COVID-19 pandemic, which has become endemic globally with two waves per year.

NanoViricides is focused on advancing NV-387 into Phase II human clinical trials, with plans to develop the drug for RSV, COVID-19, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company's platform technology is based on the TheraCour® nanomedicine technology, which is licensed from AllExcel.

While the path to drug development is lengthy and capital-intensive, NanoViricides' progress with NV-387 highlights its potential to address unmet medical needs in the treatment of viral infections and their associated health risks. The company's forward-looking statements, however, underscore the risks and uncertainties associated with the development and commercialization of its drug candidates.

References:
[1] https://www.marketscreener.com/news/nanoviricides-says-nv-387-antiviral-drug-could-help-reduce-metastatic-cancer-resurgence-ce7c51dcd981f123
[2] https://www.morningstar.com/news/accesswire/1061948msn/a-drug-that-could-reduce-metastatic-cancer-resurgence-due-to-its-anti-inflammatory-effects-in-viral-infections-is-in-clinical-trials